Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

NCT07014150 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma Resectable

Interventions

DRUG: Lenvatinib
DRUG: Iparomlimab and Tuvonralimab

Sponsor

Peking Union Medical College Hospital